GlassScriptPhysician profile
Matthew B Austin
NPI 1861753287
$5,264.77
in general payments reported to CMS, 2019-2025
35 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $67.71 · 2021: $299 · 2022: $401 · 2023: $1,485 · 2024: $1,474 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,231.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $719.29 | 2019-2025 | |
| Glaxosmithkline, LLC. | $693.67 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $575.89 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $436.82 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Abbott Laboratories | $435.66 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $401.35 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $397.16 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $217.59 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $152.90 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.16 | 2022-2025 | Jardiance, Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $137.29 | 2023-2024 | Trintellix |
| Exact Sciences Corporation | $108.40 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $102.52 | 2023-2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $84.45 | 2024-2025 | |
| Sanofi Pasteur INC. | $75.50 | 2022-2025 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Austin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.